Browse Category

NYSE:UNH News 26 September 2025 - 29 October 2025

UnitedHealth Stock Rallies After Bold Strategy Overhaul – Is 2026 a Turning Point?

UnitedHealth Stock Rallies After Bold Strategy Overhaul – Is 2026 a Turning Point?

UnitedHealth’s recent earnings and strategic shifts have drawn close market attention. The company’s Q3 2025 results beat expectations, enabling a tighter outlook. Its revenue for Q3 rose 12% to $113.2 billion unitedhealthgroup.com, with adjusted profit of $2.92 per share. That exceeded
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Stock Soars After Q3 Shock – Is a Bigger Rally Ahead?

UnitedHealth’s third-quarter report released Oct. 28 largely vindicated that turnaround strategy. Revenue climbed 12% year-over-year to $113.2 billion, helped by strong growth in both its insurance (UnitedHealthcare) and health-services (Optum) units businesswire.com. The company delivered adjusted EPS of $2.92, beating the $2.80
28 October 2025
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Market News & Today’s Financial Outlook Stocks are starting today on cautiously optimistic footing. Futures were little changed this morning after a batch of earnings delivered both relief and warnings. Netflix shocked investors with a rare earnings miss, sending its
22 October 2025
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

Current Stock Price and Performance (Oct 8 2025) UnitedHealth Group’s share price has been volatile in 2025. On 8 Oct 2025 the stock closed around $372—IndMoney quoted $372.93 while Investing.com listed $372.64 indmoney.com investing.com. Reuters reported that the last trade was $371.46, up 2.15 %
8 October 2025
PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

PSTV ERUPTS: UnitedHealthcare Backs Plus Therapeutics’ CNS Cancer Test—Stock Pops, Analysts Cheer, and the Real Winners Could Be Patients

Key facts (25–26 Sept 2025) What happened—and why it mattered UnitedHealthcare coverage win. On Sept. 25, Plus Therapeutics announced that UnitedHealthcare Insurance Company (UNH) granted national coverage for its CNSide® CSF Tumor Cell Enumeration LDT for metastatic CNS cancer, effective
26 September 2025
Go toTop